Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications

Expert Review of Clinical Pharmacology

Volumn 9, Issue 8, 2016, Pages 1091-1108

  Hanna, Diana L ^a,b   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Hoag Family Cancer Institute   (United States)

Author keywords

Angiogenesis; biomarker; EGFR; fluoropyrimidines; immunotherapy; metastatic colorectal cancer; microsatellite instability; pharmacogenetics; RAF; RAS

Indexed keywords

4 AMINO N (3 CHLORO 4 FLUOROPHENYL) N' HYDROXY 1,2,5 OXADIAZOLE 3 CARBOXIMIDAMIDE; 6 (4 CHLOROPHENYL) N ETHYL 8 METHOXY 1 METHYL 4H [1,2,4]TRIAZOLO[4,3 A][1,4]BENZODIAZEPINE 4 ACETAMIDE; ALPELISIB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; DABRAFENIB; ENSITUXIMAB; ENTRECTINIB; FAMITINIB; FLUOROURACIL; FOLINIC ACID; FUTUXIMAB; ITACITINIB; JANUS KINASE INHIBITOR; LKG 974; MM 151; NAPABUCASIN; NINTEDANIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PRI 724; PROTEIN KINASE B INHIBITOR; PYRIMIDINE DERIVATIVE; RAMUCIRUMAB; RILOTUMUMAB; RUXOLITINIB; SELUMETINIB; TAS 114; TIPIRACIL PLUS TRIFLURIDINE; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ADOPTIVE IMMUNOTHERAPY; ANTIANGIOGENIC ACTIVITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DRUG POTENTIATION; ENZYME INHIBITION; HEALTH CARE QUALITY; HUMAN; MAINTENANCE THERAPY; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PHARMACOGENOMICS; PRIMARY TUMOR; REVIEW; TUMOR REGRESSION; ANIMAL; COLORECTAL NEOPLASMS; DRUG DESIGN; GENETICS; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROCEDURES; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PHARMACOGENETICS; PRECISION MEDICINE; SURVIVAL RATE;

EID: 84963535738     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2016.1172961     Document Type: Review

References (182)

1. L.A.Torre, F.Bray, R.L.Siegel, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262. PubMed PMID: 25651787.
2. R.J.Mayer, E.Van Cutsem, A.Falcone, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–1919. doi:10.1056/NEJMoa1414325. PubMed PMID: 25970050.• Pivotal phase III trial leading to approval of TAS-102.
3. J.Capdevila, A.Carrato, J.Tabernero, et al. What could nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer? Crit Rev Oncol Hematol. 2014. doi:10.1016/j.critrevonc.2014.05.004. PubMed PMID: 24924525.
4. Z.Saridaki, N.Androulakis, N.Vardakis, et al. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. Br J Cancer. 2012;107(12):1932–1937. doi:10.1038/bjc.2012.509. PubMed PMID: 23169296; PubMed Central PMCID: PMC3516691.
5. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–337. doi:10.1038/nature11252. PubMed PMID: 22810696; PubMed Central PMCID: PMC3401966.
6. R.P.E.Duschinsky, C.Heidelberger The synthesis of 5-fluoropyrimidines. J Am Chem Soc. 1957;79(16):4559–4560.
7. C.Heidelberger, N.K.Chaudhuri, P.Danneberg, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179(4561):663–666. PubMed PMID: 13418758.
8. P.M.Wilson, P.V.Danenberg, P.G.Johnston, et al. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol. 2014;11(5):282–298. doi:10.1038/nrclinonc.2014.51. PubMed PMID: 24732946.
9. K.Saito, H.Nagashima, K.Noguchi, et al. First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers. Cancer Chemother Pharmacol. 2014;73(3):577–583. doi:10.1007/s00280-014-2383-2. PubMed PMID: 24452393.
10. M.Nukatsuka, F.Nakagawa, T.Takechi. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with oxaliplatin on human colorectal and gastric cancer xenografts. Anticancer Res. 2015;35(9):4605–4615. PubMed PMID: 26254349.
11. F.F.Kabbinavar, J.Hambleton, R.D.Mass, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23(16):3706–3712. Epub 2005/05/04. doi:10.1200/JCO.2005.00.232. PubMed PMID: 15867200.
12. H.Hurwitz, L.Fehrenbacher, W.Novotny, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–2342. Epub 2004/06/04. doi:10.1056/NEJMoa032691350/23/2335[pii]. PubMed PMID: 15175435.
13. D.A.T.Arnold, J.Bennouna, et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study). J Clin Oncol. 2012;30(suppl):abstr CRA3503.
14. E.Van Cutsem, J.Tabernero, R.Lakomy, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clinl Oncol. 2012;30(28):3499–3506. doi:10.1200/JCO.2012.42.8201. PubMed PMID: 22949147.
15. J.Holash, S.Davis, N.Papadopoulos, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393–11398. Epub 2002/08/15. doi:10.1073/pnas.172398299. PubMed PMID: 12177445; PubMed Central PMCID: PMC123267.
16. J.Tabernero, T.Yoshino, A.L.Cohn, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499–508. doi:10.1016/S1470-2045(15)70127-0. PubMed PMID: 25877855.• Pivotal phase III trial leading to approval of ramucirumab.
17. V.Baeriswyl, G.Christofori. The angiogenic switch in carcinogenesis. Semin Cancer Biol. 2009;19(5):329–337. doi:10.1016/j.semcancer.2009.05.003. PubMed PMID: 19482086.
18. F.Hilberg, G.J.Roth, M.Krssak, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774–4782. doi:10.1158/0008-5472.CAN-07-6307. PubMed PMID: 18559524.
19. B.Kutluk Cenik, K.T.Ostapoff, D.E.Gerber, et al. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol Cancer Ther. 2013;12(6):992–1001. doi:10.1158/1535-7163.MCT-12-0995. PubMed PMID: 23729403; PubMed Central PMCID: PMC3681897.
20. A.Du Bois, J.Huober, P.Stopfer, et al. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol. 2010;21(2):370–375. doi:10.1093/annonc/mdp506. PubMed PMID: 19889612.
21. P.M.Ellis, R.Kaiser, Y.Zhao, et al. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res. 2010;16(10):2881–2889. doi:10.1158/1078-0432.CCR-09-2944. PubMed PMID: 20460487.
22. K.Mross, M.Stefanic, D.Gmehling, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res. 2010;16(1):311–319. doi:10.1158/1078-0432.CCR-09-0694. PubMed PMID: 20028771.
23. I.Okamoto, H.Kaneda, T.Satoh, et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther. 2010;9(10):2825–2833. doi:10.1158/1535-7163.MCT-10-0379. PubMed PMID: 20688946.
24. H.J.T.J.Lenz, T.Yoshino, Z.Oum’Hamed, et al. LUME-Colon 1: a double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies. J Clin Oncol. 2015;33(suppl):abstr TPS3625.
25. O.Bouche, F.Maindrault-Goebel, M.Ducreux, et al. Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. Anticancer Res. 2011;31(6):2271–2281. PubMed PMID: 21737652.
26. E.A.Van Cutsem. Phase l/lI, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 in patients with metastatic colorectal cancer. Eur J Cancer. 2011;47(Supplement 2):8–9.
27. R.Garcia-Carbonero, F.Rivera, J.Maurel, et al. An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist. 2014;19(4):350–351. doi:10.1634/theoncologist.2014-0028. PubMed PMID: 24674871; PubMed Central PMCID: PMC3983832.
28. T.Yoshino, K.Yamazaki, M.Gotoh, et al. Safety and pharmacokinetics of second-line ramucirumab plus FOLFIRI in Japanese patients with metastatic colorectal carcinoma. Anticancer Res. 2015;35(7):4003–4007. PubMed PMID: 26124348.
29. A.Zhou, W.Zhang, C.Chang, et al. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. Cancer Chemother Pharmacol. 2013;72(5):1043–1053. doi:10.1007/s00280-013-2282-y. PubMed PMID: 24043137.
30. R.S.L.Xu, K.Wang, G.Wu, et al. A randomized, double-blind, parallel-group, placebo-controlled, multicenter, phase II clinical study of famitinib in the treatment of advanced metastatic colorectal cancer. J Clin Oncol. 2015;33(suppl 3):abstr 513.
31. D.J.Jonker, C.J.O’Callaghan, C.S.Karapetis, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040–2048. doi:10.1056/NEJMoa071834. PubMed PMID: 18003960.
32. T.J.Price, M.Peeters, T.W.Kim, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014;15(6):569–579. doi:10.1016/S1470-2045(14)70118-4. PubMed PMID: 24739896.
33. C.Bokemeyer, I.Bondarenko, A.Makhson, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol. 2007;25(suppl; abstr 4035):172s.
34. C.Bokemeyer, I.Bondarenko, J.T.Hartmann, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011;22(7):1535–1546. doi:10.1093/annonc/mdq632. PubMed PMID: 21228335.
35. V.Heinemann, L.F.Von Weikersthal, T.Decker, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–1075. doi:10.1016/S1470-2045(14)70330-4. PubMed PMID: 25088940.
36. E.Van Cutsem, C.H.Kohne, I.Lang, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clinl Oncol. 2011;29(15):2011–2019. doi:10.1200/JCO.2010.33.5091. PubMed PMID: 21502544.
37. M.Peeters, T.J.Price, A.Cervantes, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clinl Oncol. 2010;28(31):4706–4713. doi:10.1200/JCO.2009.27.6055. PubMed PMID: 20921462.
38. S.Siena, A.Sartore-Bianchi, F.Di Nicolantonio, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101(19):1308–1324. doi:10.1093/jnci/djp280. PubMed PMID: 19738166; PubMed Central PMCID: PMC2758310.
39. F.Di Nicolantonio, M.Martini, F.Molinari, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clinl Oncol. 2008;26(35):5705–5712. doi:10.1200/JCO.2008.18.0786. PubMed PMID: 19001320.
40. S.Arena, B.Bellosillo, G.Siravegna, et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res. 2015;21(9):2157–2166. doi:10.1158/1078-0432.CCR-14-2821. PubMed PMID: 25623215.• Elegant account highlighting the emergence of resistance to cetuximab in CRC cell lines and patient-derived tumor tissue.
41. F.J.Sanchez-Martin, B.Bellosillo, M.Gelabert, et al. The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab-resistance mediated by EGFR extracellular domain mutations in colorectal cancer. Clin Cancer Res. 2016. doi:10.1158/1078-0432.CCR-15-2400. PubMed PMID: 26888827.• Preclinical and clinical study demonstrating the efficacy of Sym004 in cetuximab-refractory CRC.
42. N.J.Skartved, H.J.Jacobsen, M.W.Pedersen, et al. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor. Clin Cancer Res. 2011;17(18):5962–5972. doi:10.1158/1078-0432.CCR-11-1209. PubMed PMID: 21825041.
43. M.W.Pedersen, H.J.Jacobsen, K.Koefoed, et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res. 2010;70(2):588–597. doi:10.1158/0008-5472.CAN-09-1417. PubMed PMID: 20068188.
44. R.Dienstmann, A.Patnaik, R.Garcia-Carbonero, et al. Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov. 2015;5(6):598–609. doi:10.1158/2159-8290.CD-14-1432. PubMed PMID: 25962717.
45. S.Stintzing, V.Heinemann. Sym004: truly a new level of anti-EGFR treatment? Cancer Discov. 2015;5(6):578–580. doi:10.1158/2159-8290.CD-15-0441. PubMed PMID: 26037914.
46. J.D.Kearns, R.Bukhalid, M.Sevecka, et al. Enhanced targeting of the EGFR network with MM-151, an oligoclonal anti-EGFR antibody therapeutic. Mol Cancer Ther. 2015;14(7):1625–1636. doi:10.1158/1535-7163.MCT-14-0772. PubMed PMID: 25911688.
47. S.Arena, G.Siravegna, B.Mussolin, et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med. 2016;8(324):324ra14. doi:10.1126/scitranslmed.aad5640. PubMed PMID: 26843189.
48. C.H.B.M.Lieu, W.A.Harb, J.D.Kearns, et al. Safety, pharmacology, and preliminary clinical activity of MM-151: an oligocolnal anti-EGFR theraputic in patients with cetuximab-resistant CRC and other refractory solid tumors. J Clin Oncol. 2015;33(suppl 3):abstr 647.
49. M.Schirripa, H.J.Lenz. Colorectal cancer: overcoming resistance to anti-EGFR therapy - where do we stand? Nat Rev Gastroenterol Hepatol. 2016. doi:10.1038/nrgastro.2016.52. PubMed PMID: 27006256.
50. S.Kopetz, J.Desai, E.Chan, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clinl Oncol. 2015;33(34):4032–4038. doi:10.1200/JCO.2015.63.2497. PubMed PMID: 26460303; PubMed Central PMCID: PMC4669589.
51. A.Prahallad, C.Sun, S.Huang, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100–103. doi:10.1038/nature10868. PubMed PMID: 22281684.
52. R.B.Corcoran, H.Ebi, A.B.Turke, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2(3):227–235. doi:10.1158/2159-8290.CD-11-0341. PubMed PMID: 22448344; PubMed Central PMCID: PMC3308191.
53. M.K.W.J.Morris, L.Adam, F.Tian, et al. Role of MEK inhibition in improving anti-tumor responses in xenograft models of BRAF-mutated metastatic colorectal cancer. J Clin Oncol. 2016;34(suppl 4S):abstr 265.
54. R.Yaeger, A.Cercek, E.M.O’Reilly, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res. 2015;21(6):1313–1320. doi:10.1158/1078-0432.CCR-14-2779. PubMed PMID: 25589621.
55. D.S.M.V.Hong, B.E.Osta, S.Fu, et al. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol. 2015;33(suppl):abstr 3511.
56. R.B.Corcoran, C.E.Atreya, G.S.Falchook, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clinl Oncol. 2015;33(34):4023–4031. doi:10.1200/JCO.2015.63.2471. PubMed PMID: 26392102; PubMed Central PMCID: PMC4669588.
57. C.A.Van Cutsem, T.André, J.Bendell, et al. Updated results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). Ann Onc. 2015;26(suppl4):iv119LBA–07.
58. D.A.Deming, L.L.Cavalcante, S.J.Lubner, et al. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer: for submission to investigational new drugs. Invest New Drugs. 2015. doi:10.1007/s10637-015-0314-7. PubMed PMID: 26666244.
59. K.Do, G.Speranza, R.Bishop, et al. Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. Invest New Drugs. 2015;33(3):720–728. doi:10.1007/s10637-015-0212-z. PubMed PMID: 25637165.
60. H.S.Hochster, N.Uboha, W.Messersmith, et al. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015;75(1):17–23. doi:10.1007/s00280-014-2609-3. PubMed PMID: 25322874.
61. S.A.Flanigan, T.M.Pitts, T.P.Newton, et al. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clin Cancer Res. 2013;19(22):6219–6229. doi:10.1158/1078-0432.CCR-13-0145. PubMed PMID: 24045180; PubMed Central PMCID: PMC3843359.
62. I.Puzanov, C.R.Lindsay, L.Goff, et al. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(4):701–711. doi:10.1158/1078-0432.CCR-14-0303. PubMed PMID: 25212606.
63. B.A.Wilky, M.A.Rudek, S.Ahmed, et al. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. Br J Cancer. 2015;112(1):24–31. doi:10.1038/bjc.2014.515. PubMed PMID: 25268371; PubMed Central PMCID: PMC4453594.
64. S.Hong, S.Kim, H.Y.Kim, et al. Targeting the PI3K signaling pathway in KRAS mutant colon cancer. Cancer Med. 2015. doi:10.1002/cam4.591. PubMed PMID: 26715098.
65. J.Rodon, I.Brana, L.L.Siu, et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014;32(4):670–681. doi:10.1007/s10637-014-0082-9. PubMed PMID: 24652201.
66. A.J.McRee, H.K.Sanoff, C.Carlson, et al. A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Invest New Drugs. 2015. doi:10.1007/s10637-015-0298-3. PubMed PMID: 26490655.
67. R.V.E.E.Geel, J.C.Bendell, J.E.Faris, et al. Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. J Clin Oncol. 2014;32(suppl; abstr 3514):5s.
68. E.Elez, R.Van Geel, J.Bendell, et al. Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer. Ann Onc. 2015;26(suppl 4):iv120.
69. M.Kloth, V.Ruesseler, C.Engel, et al. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. Gut. 2015. doi:10.1136/gutjnl-2014-309026. PubMed PMID: 26001389.
70. E.Valtorta, C.Martino, A.Sartore-Bianchi, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Modern Pathol. 2015;28(11):1481–1491. doi:10.1038/modpathol.2015.98. PubMed PMID: 26449765.
71. S.D.Richman, K.Southward, P.Chambers, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2015. doi:10.1002/path.4679. PubMed PMID: 26690310.
72. B.Ingold Heppner, H.M.Behrens, K.Balschun, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer. 2014;111(10):1977–1984. doi:10.1038/bjc.2014.483. PubMed PMID: 25211663; PubMed Central PMCID: PMC4229629.
73. R.K.Ramanathan, J.J.Hwang, W.C.Zamboni, et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest. 2004;22(6):858–865. PubMed PMID: 15641483.
74. A.Bertotti, G.Migliardi, F.Galimi, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1(6):508–523. doi:10.1158/2159-8290.CD-11-0109. PubMed PMID: 22586653.•• An elegant account of capturing tumoral heterogeneity over time to identify clinically relevant mechanisms of resistance toward cetuximab and identify promising therapeutic targets.
75. S.M.Leto, F.Sassi, I.Catalano, et al. Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas. Clin Cancer Res. 2015;21(24):5519–5531. doi:10.1158/1078-0432.CCR-14-3066. PubMed PMID: 26296355.
76. E.Van Cutsem, C.Eng, E.Nowara, et al. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res. 2014;20(16):4240–4250. doi:10.1158/1078-0432.CCR-13-2752. PubMed PMID: 24919569; PubMed Central PMCID: PMC4371780.
77. L.Trusolino, A.Bertotti, P.M.Comoglio. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11(12):834–848. doi:10.1038/nrm3012. PubMed PMID: 21102609.
78. U.S.Kammula, E.J.Kuntz, T.D.Francone, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 2007;248(2):219–228. doi:10.1016/j.canlet.2006.07.007. PubMed PMID: 16945480.
79. M.V.Chao. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003;4(4):299–309. doi:10.1038/nrn1078. PubMed PMID: 12671646.
80. S.Pulciani, E.Santos, A.V.Lauver, et al. Oncogenes in solid human tumours. Nature. 1982;300(5892):539–542. PubMed PMID: 7144906.
81. E.Ardini, R.Bosotti, A.L.Borgia, et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol. 2014;8(8):1495–1507. doi:10.1016/j.molonc.2014.06.001. PubMed PMID: 24962792.
82. A.Sartore-Bianchi, E.Ardini, R.Bosotti, et al. Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer. J Natl Cancer Inst. 2016;108(1). doi:10.1093/jnci/djv306. PubMed PMID: 26563355; PubMed Central PMCID: PMC4712682.
83. A.Amatu, A.Somaschini, G.Cerea, et al. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. Br J Cancer. 2015;113(12):1730–1734. doi:10.1038/bjc.2015.401. PubMed PMID: 26633560; PubMed Central PMCID: PMC4701996.
84. J.Lee, H.C.Kim, J.Y.Hong, et al. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Oncotarget. 2015;6(27):24320–24332. doi:10.18632/oncotarget.4462. PubMed PMID: 26172300; PubMed Central PMCID: PMC4695188.
85. M.Russo, S.Misale, G.Wei, et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov. 2016;6(1):36–44. doi:10.1158/2159-8290.CD-15-0940. PubMed PMID: 26546295.
86. F.Pages, A.Berger, M.Camus, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353(25):2654–2666. doi:10.1056/NEJMoa051424. PubMed PMID: 16371631.
87. M.Guidoboni, R.Gafa, A.Viel, et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol. 2001;159(1):297–304. doi:10.1016/S0002-9440(10)61695-1. PubMed PMID: 11438476; PubMed Central PMCID: PMC1850401.
88. D.T.Le, J.N.Uram, H.Wang, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520. doi:10.1056/NEJMoa1500596. PubMed PMID: 26028255; PubMed Central PMCID: PMC4481136.
89. T.Azuma, S.Yao, G.Zhu, et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood. 2008;111(7):3635–3643. doi:10.1182/blood-2007-11-123141. PubMed PMID: 18223165; PubMed Central PMCID: PMC2275025.
90. K.Y.Chung, I.Gore, L.Fong, et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clinl Oncol. 2010;28(21):3485–3490. doi:10.1200/JCO.2010.28.3994. PubMed PMID: 20498386.
91. J.R.Brahmer, S.S.Tykodi, L.Q.Chow, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. doi:10.1056/NEJMoa1200694. PubMed PMID: 22658128; PubMed Central PMCID: PMC3563263.
92. S.L.Topalian, F.S.Hodi, J.R.Brahmer, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690. PubMed PMID: 22658127; PubMed Central PMCID: PMC3544539.
93. R.S.Herbst, J.C.Soria, M.Kowanetz, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567. doi:10.1038/nature14011. PubMed PMID: 25428504.
94. H.E.Kohrt, A.D.Colevas, R.Houot, et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest. 2014;124(6):2668–2682. doi:10.1172/JCI73014. PubMed PMID: 24837434; PubMed Central PMCID: PMC4089447.
95. M.S.M.M.Beg, B.R.Tan, R.D.Kim, et al. A phase II multicenter study of the chimeric monoclonal antibody NEO102 (N) in adults with refractory colorectal cancer (CC). J Clin Oncol. 2015;33(suppl):abstr e14013.
96. P.A.A.R.Moore, K.Shah, Y.Yang, et al. Development of MGD007, a gpA33 x CD3 bi-specific DART for T-cell immunotherapy of metastatic colorectal cancer. Cancer Res. 2014;74(19Suppl):Abstractnr 669.
97. F.Hong, R.D.Hansen, J.Yan, et al. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 2003;63(24):9023–9031. PubMed PMID: 14695221.
98. C.Qi, Y.Cai, L.Gunn, et al. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived beta-glucans. Blood. 2011;117(25):6825–6836. doi:10.1182/blood-2011-02-339812. PubMed PMID: 21531981; PubMed Central PMCID: PMC3128477.
99. C.Salvador, B.Li, R.Hansen, et al. Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Clin Cancer Res. 2008;14(4):1239–1247. doi:10.1158/1078-0432.CCR-07-1669. PubMed PMID: 18281559; PubMed Central PMCID: PMC2394864.
100. H.Yang, C.Bueso-Ramos, C.DiNardo, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28(6):1280–1288. doi:10.1038/leu.2013.355. PubMed PMID: 24270737; PubMed Central PMCID: PMC4032802.
101. J.Tel, S.V.Hato, R.Torensma, et al. The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. Cancer Immunol Immunother. 2012;61(7):1101–1111. doi:10.1007/s00262-011-1189-x. PubMed PMID: 22193989; PubMed Central PMCID: PMC3378839.
102. S.Shalapour, J.Font-Burgada, G.Di Caro, et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015;521(7550):94–98. doi:10.1038/nature14395. PubMed PMID: 25924065; PubMed Central PMCID: PMC4501632.
103. S.Fu, W.Hu, R.Iyer, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011;117(8):1661–1669. doi:10.1002/cncr.25701. PubMed PMID: 21472713; PubMed Central PMCID: PMC3062960.
104. Y.Li, W.Hu, D.-Y.Shen, et al. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol. 2009;200(2):177.e1-9. doi:10.1016/j.ajog.2008.08.030. PubMed PMID: 19110234.
105. J.Larkin, V.Chiarion-Sileni, R.Gonzalez, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030. PubMed PMID: 26027431.
106. M.F.Sanmamed, I.Rodriguez, K.A.Schalper, et al. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2R null immunodeficient mice. Cancer Res. 2015;75(17):3466–3478. doi:10.1158/0008-5472.CAN-14-3510. PubMed PMID: 26113085.
107. R.A.Morgan, J.C.Yang, M.Kitano, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843–851. doi:10.1038/mt.2010.24. PubMed PMID: 20179677; PubMed Central PMCID: PMC2862534.
108. M.R.Parkhurst, J.C.Yang, R.C.Langan, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19(3):620–626. doi:10.1038/mt.2010.272. PubMed PMID: 21157437; PubMed Central PMCID: PMC3048186.
109. N.Wolmark, B.Fisher, H.Rockette, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst. 1988;80(1):30–36. PubMed PMID: 3276901.
110. J.U.Gutterman, G.M.Mavligit, G.Blumenshein, et al. Immunotherapy of human solid tumors with bacillus Calmette-Guerin: prolongation of disease-free interval and survival in malignant melanoma, breast, and colorectal cancer. Ann N Y Acad Sci. 1976;277(00):135–159. PubMed PMID: 1069546.
111. G.M.Mavligit, J.U.Gutterman, M.A.Malahy, et al. Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes’ class C): prolongation of disease-free interval and survival. Cancer. 1977;40(5Suppl):2726–2730. PubMed PMID: 922710.
112. C.A.Dinarello. Interleukin-1alpha neutralisation in patients with cancer. Lancet Oncol. 2014;15(6):552–553. doi:10.1016/S1470-2045(14)70164-0. PubMed PMID: 24746840.
113. C.A.Dinarello, A.Simon, J.W.van der Meer. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633–652. doi:10.1038/nrd3800. PubMed PMID: 22850787; PubMed Central PMCID: PMC3644509.
114. S.Tomimatsu, T.Ichikura, H.Mochizuki. Significant correlation between expression of interleukin-1alpha and liver metastasis in gastric carcinoma. Cancer. 2001;91(7):1272–1276. PubMed PMID: 11283926.
115. K.L.Rock, E.Latz, F.Ontiveros, et al. The sterile inflammatory response. Annu Rev Immunol. 2010;28:321–342. doi:10.1146/annurev-immunol-030409-101311. PubMed PMID: 20307211; PubMed Central PMCID: PMC4315152.
116. D.S.Hong, F.Janku, A.Naing, et al. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs. 2015;33(3):621–631. doi:10.1007/s10637-015-0226-6. PubMed PMID: 25822109; PubMed Central PMCID: PMC4482235.
117. S.U.Moon, M.H.Kang, J.H.Sung, et al. Effect of Smad3/4 on chemotherapeutic drug sensitivity in colorectal cancer cells. Oncol Rep. 2015;33(1):185–192. doi:10.3892/or.2014.3582. PubMed PMID: 25370208.
118. S.C.Meyer, R.L.Levine. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res. 2014;20(8):2051–2059. doi:10.1158/1078-0432.CCR-13-0279. PubMed PMID: 24583800; PubMed Central PMCID: PMC3990645.
119. W.Malilas, S.S.Koh, S.Kim, et al. Cancer upregulated gene 2, a novel oncogene, enhances migration and drug resistance of colon cancer cells via STAT1 activation. Int J Oncol. 2013;43(4):1111–1116. doi:10.3892/ijo.2013.2049. PubMed PMID: 23917355.
120. M.J.Overman, S.Kopetz, G.Varadhachary, et al. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008;26(8):794–799. doi:10.1080/07357900802087242. PubMed PMID: 18798063.
121. E.Stuart, M.Buchert, T.Putoczki, et al. Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice. Mol Cancer Ther. 2014;13(2):468–474. doi:10.1158/1535-7163.MCT-13-0583-T. PubMed PMID: 24398427.
122. S.Van Schaeybroeck, M.Kalimutho, P.D.Dunne, et al. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep. 2014;7(6):1940–1955. doi:10.1016/j.celrep.2014.05.032. PubMed PMID: 24931611.
123. H.J.An, E.K.Choi, J.S.Kim, et al. INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells. Neoplasma. 2014;61(1):56–62. PubMed PMID: 24195509.
124. Y.Li, H.A.Rogoff, S.Keates, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015;112(6):1839–1844. doi:10.1073/pnas.1424171112. PubMed PMID: 25605917; PubMed Central PMCID: PMC4330785.
125. J.M.O.N.B.Hubbard, D.J.Jonker, T.R.Halfdanarson, et al. Phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 administered in combination with FOLFIRI with and without bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC). J Clin Oncol. 2016;34(suppl 4S):abstr 569.
126. K.K.E.W.Ciombor, J.M.Hubbard, P.J.O’Dwyer, et al. A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy. J Clin Oncol. 2015;33(suppl):abstr 3617.
127. Y.Miyoshi, H.Nagase, H.Ando, et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet. 1992;1(4):229–233. PubMed PMID: 1338904.
128. S.M.Powell, N.Zilz, Y.Beazer-Barclay, et al. APC mutations occur early during colorectal tumorigenesis. Nature. 1992;359(6392):235–237. doi:10.1038/359235a0. PubMed PMID: 1528264.
129. H.Clevers. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469–480. doi:10.1016/j.cell.2006.10.018. PubMed PMID: 17081971.
130. E.M.de Sousa, L.Vermeulen, D.Richel, et al. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res. 2011;17(4):647–653. doi:10.1158/1078-0432.CCR-10-1204. PubMed PMID: 21159886.
131. H.Ma, C.Nguyen, K.S.Lee, et al. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene. 2005;24(22):3619–3631. Epub 2005/03/23. doi:10.1038/sj.onc.1208433. PubMed PMID: 15782138.
132. F.Varnat, I.Siegl-Cachedenier, M.Malerba, et al. Loss of WNT-TCF addiction and enhancement of HH-GLI1 signalling define the metastatic transition of human colon carcinomas. EMBO Mol Med. 2010;2(11):440–457. doi:10.1002/emmm.201000098. PubMed PMID: 20941789; PubMed Central PMCID: PMC3394505.
133. K.P.Janssen, P.Alberici, H.Fsihi, et al. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology. 2006;131(4):1096–1109. doi:10.1053/j.gastro.2006.08.011. PubMed PMID: 17030180.
134. M.Eguchi, C.Nguyen, S.C.Lee, et al. ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription. Med Chem. 2005;1(5):467–472. Epub 2006/06/22. PubMed PMID: 16787331.
135. K.H.Emami, C.Nguyen, H.Ma, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A. 2004;101(34):12682–12687. Epub 2004/08/18. doi:10.1073/pnas.0404875101. PubMed PMID: 15314234; PubMed Central PMCID: PMCPmc515116.
136. U.Sack, W.Walther, D.Scudiero, et al. S100A4-induced cell motility and metastasis is restricted by the Wnt/beta-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell. 2011;22(18):3344–3354. doi:10.1091/mbc.E10-09-0739. PubMed PMID: 21795396; PubMed Central PMCID: PMC3172260.
137. U.Stein, F.Arlt, J.Smith, et al. Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia. 2011;13(2):131–144. PubMed PMID: 21403839; PubMed Central PMCID: PMC3033592.
138. U.Stein, F.Arlt, W.Walther, et al. The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology. 2006;131(5):1486–1500. doi:10.1053/j.gastro.2006.08.041. PubMed PMID: 17101323.
139. A.B.El-Khoueiry, Y.Ning, D.Yang, et al. A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol. 2013;31(suppl):abstr 2501.
140. K.D.Proffitt, D.M.Virshup. Precise regulation of porcupine activity is required for physiological Wnt signaling. J Biol Chem. 2012;287(41):34167–34178. doi:10.1074/jbc.M112.381970. PubMed PMID: 22888000; PubMed Central PMCID: PMC3464525.
141. B.Madan, Z.Ke, N.Harmston, et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene. 2015. doi:10.1038/onc.2015.280. PubMed PMID: 26257057; PubMed Central PMCID: PMC4650263.
142. Y.P.M.Wang, S.Jaeger, L.Bagdasarian, et al. Dual Wnt and EGFR-MAPK dependency of BRAFV600E-mutant colorectal cancer. Cancer Res. 2015;75(15Suppl):Abstractnr 2140. doi:10.1158/1538-7445AM2015-2140.
143. L.L.Fu, M.Tian, X.Li, et al. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget. 2015;6(8):5501–5516. doi:10.18632/oncotarget.3551. PubMed PMID: 25849938; PubMed Central PMCID: PMC4467383.
144. M.L.McCleland, K.Mesh, E.Lorenzana, et al. CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016;126(2):639–652. doi:10.1172/JCI83265. PubMed PMID: 26752646.
145. F.Forouhar, J.L.Anderson, C.G.Mowat, et al. Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A. 2007;104(2):473–478. doi:10.1073/pnas.0610007104. PubMed PMID: 17197414; PubMed Central PMCID: PMC1766409.
146. D.M.Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239. PubMed PMID: 22437870.
147. A.I.Thaker, M.S.Rao, K.S.Bishnupuri, et al. IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. Gastroenterology. 2013;145(2):416-25e1-4. doi:10.1053/j.gastro.2013.05.002. PubMed PMID: 23669411; PubMed Central PMCID: PMC3722304.
148. M.Takamatsu, A.Hirata, H.Ohtaki, et al. Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice. Cancer Sci. 2015;106(8):1008–1015. doi:10.1111/cas.12705. PubMed PMID: 26033215; PubMed Central PMCID: PMC4556390.
149. C.Cremolini, F.Loupakis, C.Antoniotti, et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol. 2015;26(6):1188–1194. doi:10.1093/annonc/mdv112. PubMed PMID: 25712456.• Seminal study underlining the importance of the timing and depth of response as clinically relevant biomarkers in CRC.
150. H.Piessevaux, M.Buyse, M.Schlichting, et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clinl Oncol. 2013;31(30):3764–3775. doi:10.1200/JCO.2012.42.8532. PubMed PMID: 24043732.
151. F.Loupakis, C.Cremolini, G.Masi, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371(17):1609–1618. doi:10.1056/NEJMoa1403108. PubMed PMID: 25337750.
152. L.Fornaro, S.Lonardi, G.Masi, et al. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol. 2013;24(8):2062–2067. doi:10.1093/annonc/mdt165. PubMed PMID: 23666916.
153. R.S.Kerbel, A.Grothey. Gastrointestinal cancer: rationale for metronomic chemotherapy in phase III trials. Nat Rev Clin Oncol. 2015;12(6):313–314. doi:10.1038/nrclinonc.2015.89. PubMed PMID: 25963090.
154. L.H.Simkens, H.van Tinteren, A.May, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385(9980):1843–1852. doi:10.1016/S0140-6736(14)62004-3. PubMed PMID: 25862517.• Pivotal study illustrating the clinical benefit of maintenance therapy in CRC.
155. K.Triff, K.Konganti, S.Gaddis, et al. Genome-wide analysis of the rat colon reveals proximal-distal differences in histone modifications and proto-oncogene expression. Physiol Genomics. 2013;45(24):1229–1243. doi:10.1152/physiolgenomics.00136.2013. PubMed PMID: 24151245; PubMed Central PMCID: PMC3882682.
156. F.Benedix, R.Kube, F.Meyer, et al., Colon/Rectum Carcinomas Study G. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53(1):57–64. doi:10.1007/DCR.0b013e3181c703a4. PubMed PMID: 20010352.
157. F.A.Sinicrope, M.R.Mahoney, T.C.Smyrk, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clinl Oncol. 2013;31(29):3664–3672. doi:10.1200/JCO.2013.48.9591. PubMed PMID: 24019539; PubMed Central PMCID: PMC3789216.
158. F.Loupakis, D.Yang, L.Yau, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107(3). doi:10.1093/jnci/dju427. PubMed PMID: 25713148; PubMed Central PMCID: PMC4565528.• Pooled analysis of over 2000 patients demonstrating the heterogeneity of CRC and importance of primary tumor location as a stratification factor in clinical trials.
159. P.M.Lynch, H.T.Lynch, R.E.Harris. Hereditary proximal colonic cancer. Dis Colon Rectum. 1977;20(8):661–668. PubMed PMID: 923394.
160. T.W.Sadler, J.Langman. Langman’s medical embryology. 11th ed. Philadelphia: Wolters Kluwer Lippincott Williams & Wilkins; 2010.
161. O.K.Glebov, L.M.Rodriguez, K.Nakahara, et al. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomark Prev. 2003;12(8):755–762. PubMed PMID: 12917207.
162. E.Oikonomou, E.Koustas, M.Goulielmaki, et al. BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget. 2014;5(23):11752–11777. PubMed PMID: 25361007; PubMed Central PMCID: PMC4322985.
163. S.Y.Brule, D.J.Jonker, C.S.Karapetis, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 2015;51(11):1405–1414. doi:10.1016/j.ejca.2015.03.015. PubMed PMID: 25979833.
164. E.Van Cutsem, C.H.Kohne, E.Hitre, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–1417. doi:10.1056/NEJMoa0805019. PubMed PMID: 19339720.
165. S.Tejpar, L.Shen, X.Wang, et al. Integrating biomarkers in colorectal cancer trials in the West and China. Nat Rev Clin Oncol. 2015;12(9):553–560. doi:10.1038/nrclinonc.2015.88. PubMed PMID: 25963094.
166. Y.Wang, E.J.Poulin, R.J.Coffey. LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Br J Cancer. 2013;108(9):1765–1770. doi:10.1038/bjc.2013.138. PubMed PMID: 23558895; PubMed Central PMCID: PMC3658528.
167. J.Guinney, R.Dienstmann, X.Wang, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–1356. doi:10.1038/nm.3967. PubMed PMID: 26457759; PubMed Central PMCID: PMC4636487.
168. N.K.Gillis, J.N.Patel, F.Innocenti. Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin Pharmacol Ther. 2014;95(3):269–280. doi:10.1038/clpt.2013.214. PubMed PMID: 24136381; PubMed Central PMCID: PMC4128332.
169. M.J.Deenen, D.Meulendijks, A.Cats, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clinl Oncol. 2016;34(3):227–234. doi:10.1200/JCO.2015.63.1325. PubMed PMID: 26573078.•• A population-based analysis illustrating the clinical utility of pharmacogenomic-based fluoropyrimidine dosing in cancer patients.
170. W.Zhang, O.A.Press, C.A.Haiman, et al. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J Clinl Oncol. 2007;25(24):3726–3731. doi:10.1200/JCO.2007.11.4710. PubMed PMID: 17704422.
171. S.T.Pullarkat, J.Stoehlmacher, V.Ghaderi, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001;1(1):65–70. PubMed PMID: 11913730.
172. D.Caronia, M.Martin, J.Sastre, et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res. 2011;17(7):2006–2013. doi:10.1158/1078-0432.CCR-10-1741. PubMed PMID: 21325291.
173. W.Zhang, M.Gordon, A.M.Schultheis, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clinl Oncol. 2007;25(24):3712–3718. doi:10.1200/JCO.2006.08.8021. PubMed PMID: 17704420.
174. N.B.Volz, S.Stintzing, W.Zhang, et al. Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Pharmacogenomics J. 2015;15(1):69–76. doi:10.1038/tpj.2014.40. PubMed PMID: 25069475.
175. A.Sebio, A.Gerger, S.Matsusaka, et al. Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer. Pharmacogenet Genomics. 2015;25(1):30–37. doi:10.1097/FPC.0000000000000101. PubMed PMID: 25379721; PubMed Central PMCID: PMC4260998.
176. A.Sebio, S.Matsusaka, W.Zhang, et al. Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer. Pharmacogenomics J. 2015. doi:10.1038/tpj.2015.64. PubMed PMID: 26370619.
177. Y.Ning, A.Gerger, W.Zhang, et al. Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy. Mol Cancer Ther. 2014;13(2):528–539. doi:10.1158/1535-7163.MCT-13-0646. PubMed PMID: 24170770; PubMed Central PMCID: PMC3945969.
178. A.Gerger, A.El-Khoueiry, W.Zhang, et al. Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2011;17(17):5783–5792. doi:10.1158/1078-0432.CCR-11-1115. PubMed PMID: 21791631; PubMed Central PMCID: PMC3174848.
179. A.Pohl, A.El-Khoueiry, D.Yang, et al. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics J. 2013;13(2):173–180. doi:10.1038/tpj.2011.61. PubMed PMID: 22231565; PubMed Central PMCID: PMC3326190.
180. D.Lambrechts, H.J.Lenz, S.De Haas, et al. Markers of response for the antiangiogenic agent bevacizumab. J Clinl Oncol. 2013;31(9):1219–1230. doi:10.1200/JCO.2012.46.2762. PubMed PMID: 23401453.
181. F.Loupakis, C.Antoniotti, C.Cremolini, et al. Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. Pharmacogenomics J. 2014;14(4):322–327. doi:10.1038/tpj.2014.1. PubMed PMID: 24513691.
182. W.S.Wang, P.M.Chen, T.J.Chiou, et al. Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clin Cancer Res. 2007;13(12):3597–3604. doi:10.1158/1078-0432.CCR-06-2601. PubMed PMID: 17575224.